本品は獣医師様及び日本税関で止められた際、ご自身で通関手続きが可能な方、もしくは弊社による通関手続き代行料として別途4900円（数量６点まで）をお支払い頂いたお客様のみに発送致します。

（１）獣医師様は、日本税関で止められましても、通関手続きなし（フリーパス）で問題なく商品がお受け取りできます。

（２）獣医師様以外の方は、税関で止められた場合、通関手続きが必要になりますが、手続きをされることでお受け取りが可能です。獣医師様以外のお客様がご自身で税関対応される場合は獣医師様発行の処方箋が必要になります。

（３）獣医師様以外のご自身での税関対応が不可のお客様には手続き代行料として別途4900円（数量６点まで）をお支払い頂きましたら、弊社側で手続き代行し、お手元にお届け致します。

＜備考＞

・(1)、(2)に該当するお客様に関しまして税関対応・通関手続きの具体的な方法は、日本税関で止められた場合にご連絡差し上げます。

・(3)に該当するお客様に関しましてはご注文後、自動送信で送られてくる確認メールに「税関対応依頼」と記載し、返信頂ければ、こちらから改めてご連絡差し上げます。

詳細はこちら→注射液のご注文につきまして。

（商品説明）

ネコインターフェロン（組み換え型）を有効成分とるする猫⇒ネコカリシウィルス感染症、犬⇒イヌパルボウィルス感染症に効果を発揮する治療薬。

日本では商品名「インターキャット」という商品名でイヌパルボウィルス感染症、ネコ白血病ウィルス感染症、ネコ免疫不全ウィルス感染症の治療薬として流通しています。

在庫保有不可商品ですので、都度取り寄せ発送となります。

お手元にお届けできるまで１４日～２１日程度、日数がかかります。

（ヨーロッパ製）

（使用法）

ネコカリシウイルス感染症:

本剤1バイアル「ネコインターフェロン（組換え型）として1000万単位(10MU)」を用時日局生理食塩液1mLにて溶解。

通常1回体重1kg当たりネコインターフェロン（組換え型）として2.5〜5MUを静脈内に注射する。投与回数としては、1日1回とし、通常隔日投与を3回行う。

イヌパルボウイルス感染症：

本剤1バイアル「ネコインターフェロン（組換え型）として1000万単位(10MU)」を用時日局生理食塩液1mLにて溶解。

通常1回体重1kg当たりネコインターフェロン（組換え型）として1〜2.5MUを静脈内に注射する。投与回数としては、1日1回とし、通常連日投与を3回行う。

必ず獣医師の指示監督の従い、適切に投与して下さい。

（使用期限）

原則注文日より１年以上有効のもの

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We are going to ship this item only to vets and orderers who go throug costoms if the parcel is stopped by Custom.

（１）Vets can receive this item without any procedure.

（２）Orderes who are not vets need to make customs clearance procedures and they need a prescription issued by a vet.

Virbagen  Omega 10MU (Interferon)  2 Vial

Composition

Vial containing lyophylisate.

Active substance 10 MU presentation:

Recombinant omega interferon of feline origin 10 MU*/vial.

*MU: Million units.

Excipients:

Sodium chloride, D-sorbitol, gelatin.

Vial containing solvent: isotonic sodium chloride solution 1ml.

Pharmaceutical form

Powder and solvent for suspension for injection.

Clinical particulars

Target species: Dogs and Cats

Incications, contra indications, etc

For the reduction in mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.

Vaccination during and after Virbagen Omega treatment is contra-indicated until the dog appears to have recovered.

Cats :

Treatment of cats infected with FeLV and/or FIV, in non-terminal clinical stages, from the age of 9

weeks. In a field study conducted, it was observed that there was :

- a reduction of clinical signs during the symptomatic phase (4 months)

- a reduction of mortality :

• in anaemic cats, mortality rate of about 60% at 4, 6, 9 and 12 months was reduced by approximately 30% following treatment with interferon.

• in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20% following treatment with interferon. In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.

In some cases during treatment the following transient clinical signs may be onserved:

Hyperthermia (3-6 hours after injection)

Vomiting

Soft faeces to mild diarrhoea, in cats only.

In addition, a slight decrease in white blood cells, platelets and red blood cells, and rise in the concentration of alanine aminotransferase may be observed. These parameters return to normal in the week following the last injection.

Transient fatigue during the treatment, in cats only.

Special precautions for use

Dogs and cats: it was shown that strict compliance with the recommended posology is compulsory to achieve clinical benefit.

Cats: In case of repeated treatments of chronic diseases associated with hepatic, cardiac and renal failure, the corresponding disease has to be monitored prior to administration of VIRBAGEN OMEGA. Fluid therapy and other supplementary supportive treatment are necessary to improve prognosis.

The product should be used with the accompanying solvent only.

Pregnancy and lactation

The safety of Virbagen Omega has not been established during pregnancy and lactation.

Interactions with other medicaments ans other forms of interaction

The use of supplementary supportive treatments improves prognosis. No interaction has been observed during the treatment with VIRBAGEN OMEGA together with antibiotics, solution for rehydration, vitamins and non steroidal anti-inflammatory agents. However, as specific information on possible interactions of interferon with other products are missing, supplementary supportive treatments should be used cautiously and after a thorough risk/benefit analysis.

No information is available on the safety and efficacy from the concurrent use of this product with any other vaccine. For dogs, it is recommended that no vaccines should be administered until the animal appears to have recovered. Cat vaccination during and after VIRBAGEN OMEGA treatment is contraindicated as both FeLV and FIV infections are known to be immunosuppressive.

Dosage and method of administration

The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain a solution containing 10 MU of recombinant interferon.

Dogs:

The reconstituted product should be injected intravenously once daily for 3 consecutive days. The dose is 2.5 MU/kg bodyweight.

Cats:

The reconstituted product should be injected subcutaneously once daily for 5 consecutive days. The dose is 1 MU/kg bodyweight. Three separate 5-day treatments must be performed at day 0, day 14 and day 60.

Overdose 

After a tenfold overdose in both dog and cat the following clinical signs have been observed :

• mild lethargy and drowsiness

• slight increase of body temperature.

• slight increase of respiratory rate

• slight sinus tachycardia.

These clinical signs disappear within 7 days without any particular treatment.

Special warnings

No information on the induction of long-term side effects is available in dog and cat, especially for autoimmune disorders. Such side effects have been described after multiple and long-term administration of type I interferon in man. The possibility of occurrence of autoimmune disorders in treated animals cannot therefore be ruled out and has to be balanced with the risk associated with FeLV/FIV infections.

Efficacy of the product on cats with a tumorous form of the infection by FeLV, or cats infected by FeLV or coinfected by FIV in terminal stages was not tested.

In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.

Withdrawal period

not applicable.

Special precautions to be taken by the person administering the medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician.

Pharmaceutical particulars

Incompatabilities

do not mix with any other vaccine/immunological product, except the solvent supplied for use with the product.

Shelf life

2 years

Storage

Store and transport at 4° C ± 14° C.  Store in the original carton.

When the product is dissolved once, store at 4° C ± 8° C

Natute and contents of container

Box containing 1 vial (glass with stopper) of powder fraction and 1 vial (glass with stopper) with 1 ml of solvent.